Status:
RECRUITING
Congenital Athymia Patient Registry
Lead Sponsor:
Sumitomo Pharma Switzerland GmbH
Conditions:
Complete DiGeorge Anomaly
Complete DiGeorge Syndrome
Eligibility:
All Genders
Up to 21 years
Brief Summary
This Congenital Athymia Patient Registry is an observational exposure-based registry study. It uses a prospective cohort design to follow patients who have been treated with RETHYMIC. Clinical studie...
Detailed Description
This Congenital Athymia Patient Registry is an observational exposure-based registry study. It uses a prospective cohort design to follow patients who have been treated with RETHYMIC. Clinical studie...
Eligibility Criteria
Inclusion
- Pediatric patients diagnosed with Congenital Athymia:
- Who are scheduled for implantation with RETHYMIC within the next 30 days, or who were treated with RETHYMIC within the previous 60 days.
- Who have provided written informed consent directly, or written informed consent has been provided by the patient, the parent, or legal guardian.
Exclusion
- Written informed consent cannot be obtained.
Key Trial Info
Start Date :
May 25 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2026
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT05329935
Start Date
May 25 2022
End Date
April 1 2026
Last Update
August 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke University School of Medicine
Durham, North Carolina, United States, 27710